These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17606315)

  • 21. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
    Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of cervical cancer: where immunology meets diagnostics.
    Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
    Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
    Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
    Kohl I
    Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Implementation of HPV vaccination in Germany].
    Schreckenberger C; Kaufmann AM; Schneider A
    Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies.
    Canfell K; Shi JF; Lew JB; Walker R; Zhao FH; Simonella L; Chen JF; Legood R; Smith MA; Nickson C; Qiao YL
    Vaccine; 2011 Mar; 29(13):2487-94. PubMed ID: 21211586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
    Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
    Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
    Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
    Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.
    Colantonio L; Gómez JA; Demarteau N; Standaert B; Pichón-Rivière A; Augustovski F
    Vaccine; 2009 Sep; 27(40):5519-29. PubMed ID: 19616499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
    BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
    Delvenne P
    Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
    Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
    Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.